Patent assignee · IN · COMPANY

Cipla Limited

176Patents
136Active
176Granted
53Portfolio score

Filing activity: Dec 10, 2001 → Jul 12, 2022 · 56 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US8522775B2 Dry powder inhaler Human Necessities 50 Active
USD590495S1 Multidose inhaler General 49 Expired
USD590938S1 Multidose inhaler General 44 Expired
US7404400B2 Spacer device for inhaler Human Necessities 30 Expired
US8168620B2 Combination of azelastine and steroids Human Necessities 19 Expired
US8464914B2 Valve for an aerosol device Human Necessities 19 Active
US7638627B2 Process of preparing imatinib and imatinib prepared thereby Human Necessities 17 Expired
USD591856S1 Mouth piece General 15 Expired
US8304405B2 Combination of azelastine and ciclesonide for nasal administration Human Necessities 14 Active
US8318709B2 Combination of azelastine and mometasone for nasal administration Human Necessities 14 Active
US8962601B2 Pharmaceutical products and composition comprising specific anticholinergic agents, β-2 agonists and corticosteroids Human Necessities 13 Active
USD646780S1 Inhaler device General 11 Expired
US9901585B2 Combination of azelastine and fluticasone for nasal administration Human Necessities 11 Active
USD631956S1 Aerosal delivery device General 10 Expired
US8633234B2 Rifaximin Emerging Cross-Sectional Technologies 9 Active
US7395821B2 Multi-dose inhaler Human Necessities 9 Expired
US9227990B2 Antiviral phosphonate analogues and process for preparation thereof Human Necessities 9 Active
US8163723B2 Combination of azelastine and steroids Human Necessities 9 Active
USD590057S1 Inhaler General 8 Expired
US8006695B2 Inhaler Human Necessities 7 Active
US7285669B2 Process for preparing 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole Chemistry; Metallurgy 7 Expired
US10940274B2 Nasal spray assembly Human Necessities 6 Active
USD605497S1 Cantilever General 6 Expired
US10301282B2 Polymorphic form X of nilotinib dihydrochloride hydrate Chemistry; Metallurgy 6 Active
US9913853B2 Stabilized liquid fosaprepitant formulations Human Necessities 5 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.